Phil Brandish

Phil Brandish joined AI Proteins in February 2025 and serves as Chief Scientific Officer. He brings 25 years of drug discovery, research and development experience from large pharma and biotech.

Prior to joining AI Proteins, Phil was VP and then SVP of Immuno-Oncology at Bicycle Therapeutics, where he built a US-based science team focused on immunology, advanced a Nectin-4/CD137 immune engager (BT7480) into the clinic, and helped build a robust internal pipeline of consisting of toxin conjugates (BTCs), targeted radiopharm programs, and IO agonist programs. At the culmination of a long career at Merck, spanning basic research to clinical POC, across therapeutic areas and across therapeutic modalities, Phil led a cancer immunology research team in Boston, and co-led three first-in-class clinical stage oncology programs.

Phil received a B.Sc. in Biochemistry (1st class) from the University of Southampton, England, and gained his Ph.D. in mechanistic enzymology in the Chemistry department. Phil completed a post-doctoral fellowship at the University of Michigan before moving to industry.